Exemestane-d2

• Description:

  Exemestane-d2 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

• Product Name Alternative:

  FCE 24304-d2; EXE-d2

• UNSPSC:

  12352211

• Target:

  Cytochrome P450; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Metabolic Enzyme/Protease; Others

• Field of Research:

  Cancer; Endocrinology

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@]12[C@]3([H])[C@](CC(C1=CC(C=C2)=O)=C)([H])[C@@]4([H])[C@](CC3)(C(C([2H])([2H])C4)=O)C

• Molecular Formula:

  C20H22D2O2

• Molecular Weight:

  298.42

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Di Salle, E., et al., Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol, 1994. 49 (4-6) : p. 289-94.; Miki, Y, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2004 Sep 1;10 (17) :5717-23.; Goss, P.E., et al., Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res, 2004. 10 (17) : p. 5717-23.; Zaccheo, T., D. Giudici, and E. Di Salle, Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol, 1993. 44 (4-6) : p. 677-80.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• Isoform:

  Aromatase/CYP19A1